Clinical trials: Lymphatic Filariasis
Mycobacterium Infections, Tuberculosis
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
Background: Lymphatic filariasis is an infection that is caused by small, thread-like worms. It is spread by mosquitoes, and causes fever, chills, and headaches.
- Conditions
- Mycobacterium Infections, Tuberculosis, Filariasis, Latent Tuberculosis
- Trial name
- NCT01547884
- Where
- 2 sites in United States, India
- Volunteers
- 4,268 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness)
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
Onchocerciasis or river blindness is an infectious disease caused by a parasitic worm. It spreads through the bite of an infected blackfly.
- Trial name
- NCT06412926
- Testing
- BAY 44-4400
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Loiasis With Positive Blood Microfilaremia, Loiasis
21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
Our aim is to test the hypothesis that a 3-week course of albendazole 400 mg daily is safe and can progressively reduce Loa loa microfilarial densities in subjects with microfilaremia.
- Trial name
- STOP-FiLAR-ALB (NCT06613997)
- Testing
- Albendazole 400mg
- Volunteers
- 100 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Lymphatic Filariasis, Onchocerciasis
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Approximately 4,000 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas.
- Conditions
- Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections
- Trial name
- NCT02032043
- Testing
- Annual versus Semiannual Albendazole plus Ivermectin MDA
- Where
- Côte d’Ivoire
- Volunteers
- 14,457 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
The primary purpose of this phase 3b study is to determine the safety and efficacy of moxidectin administration twice a year, compared to once a year, in maintaining undetectable levels in skin of O.
- Trial name
- NCT03876262
- Testing
- Moxidectin, Ivermectin
- Where
- Democratic Republic of the Congo
- Volunteers
- 323 people
- Sponsor
- Medicines Development for Global Health
Lymphatic Filariasis
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
According to the World Health Organization, lymphatic filariasis, a mosquito-borne parasitic disease, is the second leading cause of disability worldwide.
- Trial name
- NCT01629771
- Where
- 2 sites in United States, India
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Lymphatic Filariasis
Moxidectin for LF, Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- Trial name
- NCT04410406
- Testing
- Ivermectin, Diethylcarbamazine, Albendazole
- Where
- Côte d’Ivoire
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Gout
Prevalence of Abnormalities in Ultrasonography of Joint and Tendons in Patients With Gout
Gout is the most frequent inflammatory arthritis in men after 40 years, with a prevalence of 0.9% in France. This disease is characterized by deposits of sodium urate crystals in joints, tendons and soft tissues, which can be…
- Trial name
- EchoGoutte (NCT05546593)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parasitic Diseases, Bacterial Diseases
Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination
The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin…
- Trial name
- AZIVAL (NCT01586169)
- Testing
- triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
- Where
- Mali
- Volunteers
- 3,000 people
- Sponsor
- Centre d'Appui à la lutte contre la Maladie
Mansonella Perstans Infection, Buruli Ulcer
Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana
This study will determine the influence of doxycycline treatment against Wolbachia/M. perstans on immunity against concomitant mycobacterial infections in healthy M. perstans infected individuals.
- Conditions
- Mansonella Perstans Infection, Buruli Ulcer, Tuberculosis, Co-infection
- Trial name
- Map2Co (NCT02281643)
- Testing
- Doxycycline
- Where
- Ghana
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kwame Nkrumah University of Science and Technology
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Onchocercal Subcutaneous Nodule, Onchocerciasis
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
This study will investigate the safety and effectiveness of combination regimens in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin…
- Conditions
- Onchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca Infection
- Trial name
- NCT06070116
- Testing
- Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole
- Where
- Liberia
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Malaria, Filarial Infection
Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites
This study, conducted by NIH and the University of Bamako in Mali, Africa, will study the effect of concurrent infections with malaria and filariasis on patients' immune response.
- Trial name
- NCT00341666
- Where
- Mali
- Volunteers
- 360 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Loiasis
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood.
- Trial name
- NCT01111305
- Testing
- Reslizumab, Diethylcarbamazine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Loiasis
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
- Trial name
- STOP-FiLAR (NCT06252961)
- Testing
- Levamisole 3 days, Levamisole 5 days
- Where
- 2 sites in Republic of the Congo
- Volunteers
- 99 people
- Sponsor
- Programme National de Lutte contre l'Onchocercose, Republic of the Congo